Hematopoiesis News Volume 13.15 | Apr 19 2022

    By
    Justin.choi
    -
    0
    27






    2022-04-19 | HN 13.14


    Hematopoiesis News by STEMCELL Technologies
    Vol. 13.14 – 19 April, 2022
    TOP STORY

    Mapping Human Hematopoietic Stem Cells from Hemogenic Endothelium to Birth

    Scientists created a single-cell transcriptome map of human hematopoietic tissues from the first trimester to birth and found that the HSC signature RUNX1+HOXA9+MLLT3+MECOM+HLF+SPINK2+ distinguished HSCs from progenitors throughout gestation.
    [Nature]

    AbstractPress Release

    Easy250 EasySep Magnet for rapid immune cell isolation from large-volume samples.
    PUBLICATIONSRanked by the impact factor of the journal

    Single Cell Analyses Identify a Highly Regenerative and Homogenous Human CD34+ Hematopoietic Stem Cell Population

    Researchers uncovered an uncharacterized human CD34+ HSC population. The CD34+EPCR+(CD38/CD45RA)− HSCs have a high repopulating and self-renewal abilities, reaching a stem cell frequency of about one in three cells, the highest described to date.
    [Nature Communications]

    Full Article

    Inhibition of the Succinyl Dehydrogenase Complex in Acute Myeloid Leukemia Leads to a Lactate-Fuelled Respiratory Metabolic Vulnerability

    Scientists uncovered that acute myeloid leukemia patients with FLT3 internal tandem duplications were characterized by a high expression of succinate-CoA ligases and high activity of mitochondrial electron transport chain complex II, thereby driving high mitochondrial respiration activity linked to the Krebs cycle.
    [Nature Communications]

    Full Article

    A Leukemia-Protective Germline Variant Mediates Chromatin Module Formation via Transcription Factor Nucleation

    To better understand the molecular mechanisms underlying “variable chromatin modules” (VCMs) formation, the authors mechanistically dissect a VCM-modulating noncoding variant that was associated with reduced chronic lymphocytic leukemia predisposition and disease progression.
    [Nature Communications]

    Full Article

    Targeting the Lysine-Specific Demethylase 1 Rewires Kinase Networks and Primes Leukemia Cells for Kinase Inhibitor Treatment

    Scientists revealed a potential therapeutic strategy for a subset of AML and suggest that activated MEK signaling might be a source of resistance to LSD1 inhibitors now being tested in patients with AML.
    [Science Signaling]

    Full ArticlePress Release

    Leukemia Inhibitory Factor Drives Glucose Metabolic Reprogramming to Promote Breast Tumorigenesis

    Investigators found that leukemia inhibitory factor increased glucose uptake and drove glycolysis, contributing to breast tumorigenesis.
    [Cell Death & Disease]

    Full Article

    Defenestrated Endothelium Delays Liver-Directed Gene Transfer in Hemophilia A Mice

    Researchers examined the efficacy of liver-directed gene transfer in FVIII knock out mice by adeno associated vectors 8-GFP.
    [Blood Advances]

    Abstract

    Utility of the Treatment-Related Mortality (TRM) Score to Predict Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

    Using single-institution data from 861 adults with AML, we retrospectively examined the TRM score, originally developed to predict early mortality following induction chemotherapy, as a predictor of post-hematopoietic cell transplantation outcome.
    [Leukemia]

    Abstract

    Comparison of the Impact of Two Post-remission Therapy Regimens on Cardiac Events in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

    Scientists compared the incidence of cardiac events and event-free survival after allogeneic hematopoietic stem cell transplantation at two Japanese hospitals between high-dose cytarabine and anthracycline-containing post-remission therapy to clarify the safety of post-remission therapy.
    [International Journal of Hematology]

    Full Article

    Tips to prepare for your next conference or networking event
    REVIEWS

    Controversies about Immunoglobulin Replacement Therapy in HSCT Recipients with Hypogammaglobulinemia

    Clinical guidelines for chronic lymphocytic leukemia describe immunoglobulin administration in patients with a low IgG who have experienced a severe/repeated bacterial infection.
    [Bone Marrow Transplantation]

    Full Article

    INDUSTRY AND POLICY NEWS

    Exelixis Announces Initiation of First-in-Human Phase I Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma

    Exelixis, Inc. announced initiation of the dose-escalation stage of the first-in-human phase I trial of XL114, a novel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 complex, as a monotherapy in patients with non-Hodgkin’s lymphoma who have received prior standard therapies.
    [Exelixis, Inc.]

    Press Release

    FEATURED EVENT

    European Immunogenetics and Histocompatibility Conference

    May 17 – 20, 2022
    Amsterdam, Netherlands

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral or Research Associate – Hematopoiesis and Leukemic Transformation

    University of Manitoba – Winnipeg, Manitoba, Canada

    Postdoctoral Research Associate – Pharmaceutical Sciences

    St. Jude Children’s Research Hospital – Memphis, Texas, United States

    Postdoctoral Research Associate – Hematology/Oncology

    University of Illinois Chicago – Chicago, Illinois, United States

    Postdoctoral Researcher – Leukemia Subtypes

    University Children’s Hospital of Zurich – Zurich, Switzerland

    Postdoctoral Research Associate – Oncology

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter